255 related articles for article (PubMed ID: 21707497)
1. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.
Candolfi M; Kroeger KM; Xiong W; Liu C; Puntel M; Yagiz K; Muhammad AG; Mineharu Y; Foulad D; Wibowo M; Assi H; Baker GJ; Lowenstein PR; Castro MG
Anticancer Agents Med Chem; 2011 Oct; 11(8):729-38. PubMed ID: 21707497
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
3. Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines.
Cimini A; Mei S; Benedetti E; Laurenti G; Koutris I; Cinque B; Cifone MG; Galzio R; Pitari G; Di Leandro L; Giansanti F; Lombardi A; Fabbrini MS; Ippoliti R
J Cell Physiol; 2012 Mar; 227(3):939-51. PubMed ID: 21503892
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery.
Yoon DJ; Kwan BH; Chao FC; Nicolaides TP; Phillips JJ; Lam GY; Mason AB; Weiss WA; Kamei DT
Cancer Res; 2010 Jun; 70(11):4520-7. PubMed ID: 20460527
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery approaches for the treatment of glioblastoma multiforme.
Fakhoury M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1365-73. PubMed ID: 26046399
[TBL] [Abstract][Full Text] [Related]
7. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapies in glioblastoma multiforme.
McNamara MG; Mason WP
Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
10. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
[TBL] [Abstract][Full Text] [Related]
11. Imaging of convection enhanced delivery of toxins in humans.
Mehta AI; Choi BD; Raghavan R; Brady M; Friedman AH; Bigner DD; Pastan I; Sampson JH
Toxins (Basel); 2011 Mar; 3(3):201-6. PubMed ID: 22069706
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
13. Prolonged survival upon ultrasound-enhanced doxorubicin delivery in two syngenic glioblastoma mouse models.
Kovacs Z; Werner B; Rassi A; Sass JO; Martin-Fiori E; Bernasconi M
J Control Release; 2014 Aug; 187():74-82. PubMed ID: 24878186
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drug-loaded hydrogels as drug delivery systems for the local treatment of glioblastoma.
Bastiancich C; Danhier P; Préat V; Danhier F
J Control Release; 2016 Dec; 243():29-42. PubMed ID: 27693428
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the Role of Glutamate Signaling in Glioblastoma Multiforme: Current Therapeutic Modalities and Future Directions.
Mollazadeh H; Mohtashami E; Mousavi SH; Soukhtanloo M; Vahedi MM; Hosseini A; Afshari AR; Sahebkar A
Curr Pharm Des; 2020; 26(37):4777-4788. PubMed ID: 32493186
[TBL] [Abstract][Full Text] [Related]
16. Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.
Rustamzadeh E; Li C; Doumbia S; Hall WA; Vallera DA
J Neurooncol; 2003 Oct; 65(1):63-75. PubMed ID: 14649886
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
18. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Wykosky J; Hu J; Gomez GG; Taylor T; Villa GR; Pizzo D; VandenBerg SR; Thorne AH; Chen CC; Mischel PS; Gonias SL; Cavenee WK; Furnari FB
Cancer Res; 2015 Jan; 75(2):394-404. PubMed ID: 25432173
[TBL] [Abstract][Full Text] [Related]
19. The role of CD44 in glioblastoma multiforme.
Mooney KL; Choy W; Sidhu S; Pelargos P; Bui TT; Voth B; Barnette N; Yang I
J Clin Neurosci; 2016 Dec; 34():1-5. PubMed ID: 27578526
[TBL] [Abstract][Full Text] [Related]
20. STAT3 as a Therapeutic Target for Glioblastoma.
Liu Y; Li C; Lin J
Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
